The ModifiSite™ Farnesyltransferase Activity Assay Kit uses fluorometric peptide labeling to screen FTase inhibitors, aiming to block Ras signaling in cancer. This assay validates drugs that prevent the membrane localization of oncogenic proteins. It supports the development of targeted cancer therapies by quantifying the activity of the prenylation machinery.
Features
Fluorometric peptide labeling; Screening FTase inhibitors to block Ras signaling in cancer.
Process Relevance
Ras Signaling Inhibition
Application Stage
Lead Optimization
Applications
Ras protein modification and cancer therapy research.
Qualified With
Internal performance validation using reference standards under defined assay conditions.
Store at −20 °C upon receipt to maintain reagent stability. Follow recommended handling procedures to ensure consistent assay performance.
Storage Comment
Avoid repeated freeze-thaw cycles. During use, minimize the time components are exposed to room temperature and return them promptly to −20 °C storage after handling. Do not store at elevated temperatures for extended periods.
Expiry Date
6 months under recommended storage conditions to ensure optimal performance.
Note
For bulk pricing or custom reagent inquiries, please contact us by email or phone. Products are shipped on ice via FedEx.
Restrictions
For Research Use Only (RUO). Not intended for diagnostic or therapeutic use.
Shipping
Shipped on ice under temperature-controlled conditions.
Background
Farnesyltransferase attaches a farnesyl group to proteins facilitating membrane association. Ras proteins require farnesylation for activity; inhibitors are explored as cancer therapeutics.